

THE ROAD TO HCV ELIMINATION

When it comes to global hepatitis C virus (HCV) elimination, we believe time matters. We are just 10 years away from the World Health Organization (WHO) 2030 goal for HCV elimination.¹ HCV elimination is achievable, but we must work together to maximize the time we have left.

- 1989**
 The hepatitis C virus is identified. Previously it had been known only as non-A non-B hepatitis (NANBH)²
- 1990**
 Screening blood for hepatitis C begins in the US, reducing the risk of transmission through transfusion³
- 1991**
 Interferon, the first treatment for chronic hepatitis C, is approved. This treatment is administered by injection and the treatment course typically lasts between 24 and 48 weeks⁴
- 1998**
 A treatment for hepatitis C using a combination of interferon and ribavirin is approved⁵
- 2007**
 Deaths from hepatitis C surpass those from HIV, in the US⁶
 The World Hepatitis Alliance is founded⁷
- 2010**
 The first rapid antibody test for hepatitis C detection becomes available. Delivering results in just 20 minutes⁸
- 2011**
 The first WHO official World Hepatitis Day is held on the 28th July⁹
 First generation DAAs, called protease inhibitors, used in combination with pegylated interferon and ribavirin are developed⁹
- 2014**
 Combination DAA treatments are introduced, allowing for the first interferon-free, entirely oral treatment for some patients (genotype 1)⁹
- 2016**
 Pan-genotypic (genotypes 1-6) DAA treatments become available¹⁰
 The WHO sets the goal for the global elimination of HCV by 2030¹
- 2017**
 AbbVie Partnership with the Economist Intelligence Unit: The Path to Zero initiative to foster a global dialogue around innovative solutions towards HCV elimination¹¹
 30 out of 60 countries are still not on track to meet the 2030 elimination goal¹²
 In collaboration with viral hepatitis experts, AbbVie launches MappingHepC.com, an interactive online resource that features national and state-level US epidemiology data on HCV screening, diagnosis and treatment. This increased understanding of the patient landscape is a crucial step towards eliminating the virus in the US¹³
- 2018**
 AbbVie enters into agreement with the Medicines Patent Pool (MPP) to expand access to HCV treatments in low- and middle-income territories¹⁴
- 2019**
 AbbVie becomes a member of the Coalition for Global Hepatitis Elimination
- 2020 AND BEYOND**
 Globally, an estimated 71 million people are living with chronic HCV¹⁵
 Of those 71 million, 14 million are aware of their diagnosis
 1.76 million of those diagnosed start treatment¹⁶
 AbbVie is supporting an estimated 300 micro-elimination projects (including 53 studies) worldwide¹²
 AbbVie broadens its support of the Coalition for Global Hepatitis Elimination with a new grant to expand the coalition's reach and overall awareness

References

- World Health Organization, 2016. Draft global health sector strategies Viral hepatitis, 2016–2021. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1 Last accessed 2nd June 2020
- Bukh J, 2016. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. *Journal of hepatology*, Oct 1;65(1): S2-1.
- Selvarajah S, Busch MP, 2012. Transfusion transmission of HCV, a long but successful road map to safety. *Antivir Ther*. 17(7 Pt B):1423-1429.
- Dahiya M, et al, 2019. The Revolutionary Changes in Hepatitis C Treatment: A Concise Review. *BCM J*, vol. 61, No. 2, (72-77).
- Baker R, 1998. FDA approves new combination treatment for hepatitis C. *Food and Drug Administration*. BETA. 1998;10.
- Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD, 2012. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Annals of internal medicine*. 21;156(4):271-8. Feb
- World Hepatitis Alliance. Our Story. Available from: <https://www.worldhepatitisalliance.org/about/our-story> Last accessed 2nd June 2020
- Medscape, 2010. FDA Approves First Rapid HCV Antibody Test. Available from: <https://www.medscape.com/viewarticle/724236> Last accessed 2nd June 2020
- PhRMA, 2014. Twenty-Five Years of Progress Against Hepatitis C; Setbacks and Stepping Stones. Available from: <https://www.phrma-docs.phrma.org/sites/default/files/pdf/Hep-C-Report-2014-Stepping-Stones.pdf> Last accessed 2nd June 2020
- World Health Organization, 2018. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic hepatitis C Virus Infection. Available from: <https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1>. Last accessed 2nd June 2020
- AbbVie News Center, 2017. Can Hepatitis C Be Eliminated by 2030? On the Path to Zero. Accessed from: <https://news.abbvie.com/news/abbvie-news-briefs/can-hepatitis-c-be-eliminated-by-2030-on-path-to-zero.htm> Last Accessed 18 June, 2020
- Calleja et al, 2019. Eliminating Hepatitis C by 2030: The Role of AbbVie. Available from: <https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/virology/hcv-elimination-overview.pdf> Last accessed: 18th June 2020
- AbbVie News Center, 2018. Available from: <https://news.abbvie.com/news/press-releases/abbvie-characterizes-evolving-hepatitis-c-hcv-patient-landscape-in-united-states-using-comprehensive-dataset.htm> Last accessed 2nd June 2020
- Medicines Patent Pool, 2018. The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir. Available from: <https://www.prnewswire.com/news-releases/the-medicines-patent-pool-signs-licence-with-abbvie-to-expand-access-to-key-hepatitis-c-treatment-glecaprevir-pibrentasvir-889601742.html> Last accessed 17th June 2020
- World Health Organization, 2019. Factsheet: Hepatitis C. Available from: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c>. Last accessed 2nd June 2020
- World Health Organization, 2018. Progress Report on Access to Hepatitis C Treatment. Available from: <https://apps.who.int/iris/bitstream/handle/10665/260445/WHO-CDS-HIV-18.4-eng.pdf?sequence=1> Last accessed 17th June 2020

ABBVIE STORIES

- [How a world free from viral hepatitis is possible](#)
- [HCV elimination: The Next Frontier](#)
- [Going inside prison walls to help eliminate hepatitis C](#)
- [HCV micro-elimination: holistic approach to care in people who inject drugs](#)

Hear from some of AbbVie's partners on:

- [The importance of partnership in HCV elimination](#)
- [Removing barriers to HCV care](#)
- [The urgency to act now to eliminate HCV](#)
- [What they think it will take to achieve HCV elimination](#)